
received tafasitamab Q2W until disease progression. The primary
endpoint was objective response rate (ORR); secondary endpoints
were duration of response (DoR), progression‐free survival (PFS) and
overall survival (OS).
Results: Of 81 enrolled pts, 80 received tafasitamab +LEN and were
included in the full analysis set. As of October 30, 2020, and after
≥35 months’ follow‐up, 17 patients were still receiving tafasitamab
monotherapy. ORR was 57.5% (n =46), including a complete
response (CR) in 40% of pts (n =32) and a partial response (PR) in
17.5% of pts (n =14). Median estimated DoR was 43.9 months (95%
confidence interval [CI]: 26.1–not reached [NR]), and NR in pts who
achieved a CR (95% CI: 43.9–NR). Median estimated PFS was 11.6
months (95% CI: 6.3–45.7) (Fig.) and estimated 36‐month PFS was
41.1% (95% CI: 29.1–52.7). Median estimated OS was 33.5 months
(95% CI: 18.3–NR).
In pts who had received 1 vs ≥2 prior lines of therapy, ORR was
67.5% (n =27/40; CR: 47.5%; PR: 20.0%) vs 47.5% (n =19/40;
CR: 32.5%; PR: 15.0%). Median estimated DoR was 43.9 months
(95% CI: 9.1–NR) with 1 prior treatment and NR (95% CI: 15.0–
NR) with ≥2 prior treatments. Estimated median PFS and 36‐
month PFS were 23.5 months (95% CI: 7.4–NR) and 47.8% (95%
CI: 30.2–63.4) in pts with 1 prior treatment vs 7.6 months (95%
CI: 2.7–NR) and 34.3% (95% CI: 18.6–50.7) in those receiving ≥2
prior treatments. Median estimated OS was 45.7 months (95% CI:
24.6–NR) in pts with 1 prior treatment compared with 15.5
months (95% CI: 8.6–NR) in those receiving ≥2 prior treatments.
No unexpected toxicities or new safety signals emerged. The most
frequently reported Grade ≥3 hematological TEAEs were neu-
tropenia (0.91/pt year of exposure [PY]), thrombocytopenia (0.17/
PY), leukopenia (0.13/PY), anemia (0.09/PY), and febrile neutropenia
(0.06/PY).
Conclusions: With a median DoR of 43.9 months (NR for pts
achieving a CR), combination therapy with tafasitamab +LEN fol-
lowed by tafasitamab monotherapy provided durable responses in
pts with R/R DLBCL not eligible for ASCT, with a manageable safety
profile. These long‐term data indicate that this chemotherapy‐free
regimen can achieve prolonged disease control and survival benefit
in this pt population, especially at first relapse.
EA ‐previously submitted to ASCO and EHA 2021.
The research was funded by: MorphoSys AG, Planegg, Germany
Keywords: Aggressive B‐cell non‐Hodgkin lymphoma
Conflicts of interests pertinent to the abstract
J. Duell
Research funding: MorphoSys AG, Regeneron Pharmaceuticals
K. J. Maddocks
Honoraria: Pharmacyclics, Celgene, Seattle Genetics, MorphoSys AG,
Bristol‐Myers Squibb, Karyopharm Therapeutics, Kite/Gilead Sci-
ences, ADC Therapeutics, Genmab
Research funding: Pharmacyclics, Merck, Bristol‐Myers Squibb
E. González‐Barca
Consultant or advisory role: Janssen, Celgene, Gilead Sciences,
Kyowa Kirin, EUSA Pharma, AbbVie
Educational grants: Janssen, AbbVie, Roche
Other remuneration: Janssen, AbbVie, Takeda
W. Jurczak
Consultant or advisory role: Mei pharma, Debiopharm, Loxo, Takeda,
AstraZeneca, Beigene
Research funding: GSK, Acerta, Beigene, Nordic Nanovector, Debio-
pharm, Incyte, Genentech, Janssen, Loxo, Mei Pharma, MorphoSys,
Takeda, TG Therapeutics
A. M. Liberati
Consultant or advisory role: Incyte
Honoraria: Bristol and Mayers, Servier, Celgene, Abbvie, Amgen
Research funding: Novartis, Jannsen, Abbvie, Roche, Amgen, Sanofi
Genzyme, Celgene, BMS, Servier, Incyte, Pfizer, IQVIA, Doxopharma,
Verastem, Beigene, Oncopeptides, Karyopharma, Archigen, CTI Bio-
pharma Corp, Debiopharm, MorphoSys AG, Fibrogen, Mei Pharma,
Regeneron Pharmaceutical Inc, Dr Reddy's Laboratories
Educational grants: Amgen, Servier, Celgene, Roche, Takeda, Abbvie,
Novartis, Sanofi Genzyme, IQVIA, Verastem, BMS
A. Obr
Consultant or advisory role: Janssen
Honoraria: Roche, Janssen
Educational grants: Roche, Gilead Sciences, Janssen
Other remuneration: Roche
G. Gaidano
Consultant or advisory role: Janssen, Abbvie, AstraZeneca
Honoraria: Janssen, Abbvie, AstraZeneca
Educational grants: Janssen
Other remuneration: Janssen, Abbvie
P. Abrisqueta
Consultant or advisory role: Janssen, Celgene, Abbvie, AstraZeneca
Honoraria: Janssen, Celgene, Abbvie, AstraZeneca, Gilead Sciences
Other remuneration: Janssen, Celgene, Abbvie, AstraZeneca, Gilead
Sciences
M. Dreyling
Consultant or advisory role: AstraZeneca, Bayer, Beigene, Celgene,
Gilead Sciences, Janssen, Novartis, Roche
Honoraria: Bayer, Celgene, Janssen, Roche, Gilead Sciences
Research funding: Abbvie, Bayer, Celgene, Janssen, Roche
T. Menne
Consultant or advisory role: Kite/Gilead Sciences, Celgene, Novartis,
Amgen, Pfizer, Atara Biotherapeutics, Daiichi Sankyo/Lilly
Honoraria: Takeda, Janssen
Research funding: Janssen, AstraZeneca, Novartis
Educational grants: Amgen, Jazz Pharmaceuticals, Janssen, Celgene,
Kite/Gilead Sciences
Other remuneration: Kite/Gilead Sciences, Roche, Novartis, Pfizer
60
-
SUPPLEMENT ABSTRACTS